• Explore /
  • Poster
  • / Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with <em>BRCA1</em> or <em>BRCA2 </em>(<em>BRCA</em>)<em>-</em>mutated metastatic castration-resistant prostate cancer (mCRPC).

Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Wassim Abida

Memorial Sloan Kettering Cancer Center, New York, NY

Wassim Abida , David Campbell , Akash Patnaik , Brieuc Sautois , Jeremy David Shapiro , Nicholas J. Vogelzang , Alan Haruo Bryce , Raymond S. McDermott , Francesco Ricci , Julie Haewon Rowe , Jingsong Zhang , Andrea Loehr , Darrin Despain , Melanie Dowson , Tony Golsorkhi , Simon Chowdhury

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT02952534

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 178)

Abstract #

178

Poster Bd #

H14

Abstract Disclosures

Similar Posters

First Author: Wassim Abida

Poster

2024 ASCO Genitourinary Cancers Symposium

Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.

Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.

First Author: Rebecca Hassoun

First Author: Benedito A. Carneiro

First Author: Fadi Taza